The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise-Induced Asthma and Leads to Suppression of LPS-Stimulated TNF-α Ex Vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise-Induced Asthma and Leads to Suppression of LPS-Stimulated TNF-α Ex Vivo

Published:2002-03 Issue:3 Volume:42 Page:297-303
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Timmer Wolfgang,Leclerc Violette,Birraux Guillaume,Neuhauser Markus,Hatzelmann Armin,Bethke Thomas,Wurst Wilhelm

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference21 articles.

1. Therapeutic potential of selective PDE inhibitors in asthma;Schudt;Pulm Pharmacol Ther,1999

2. Phosphodiesterase isozymes: molecular targets for novel antiasthmatic agents;Torphy;Am J Respir Crit Care Med,1998

3. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation;Essayan;Biochem Pharmacol,1999

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The IL-4/13-induced production of M2 chemokines by human lung macrophages is enhanced by adenosine and PGE2;International Immunopharmacology;2024-02

2. Promising treatment biomarkers in asthma;Frontiers in Drug Safety and Regulation;2023-11-07

3. The immunomodulatory effects of roflumilast on tachyzoite-bradyzoite transition in a murine model of Toxoplasma gondii;International Immunopharmacology;2022-12

4. Neutrophils and Asthma;Diagnostics;2022-05-08

5. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis;Frontiers in Pharmacology;2022-04-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP